Results 71 to 80 of about 216,339 (397)

Atezolizumab plus Bevacizumab versus Sorafenib in the Chinese Subpopulation with Unresectable Hepatocellular Carcinoma: Phase 3 Randomized, Open-Label IMbrave150 Study

Liver Cancer, 2021
Introduction: Atezolizumab plus bevacizumab significantly improved overall survival (OS) and progression-free survival (PFS) versus sorafenib in patients with unresectable hepatocellular carcinoma (HCC) in IMbrave150.
S. Qin, Z. Ren, Yin-Hsun Feng, T. Yau, Baocheng Wang, Haitao Zhao, Y. Bai, S. Gu, Lindong Li, Sairy G. Hernandez, Derek-Zhen Xu, S. Mulla, Yifan Wang, H. Shao, A. Cheng   +14 more
semanticscholar   +1 more source

Bevacizumab for glioblastoma

Therapeutics and Clinical Risk Management, 2015
Individuals with glioblastoma are often characterized by older age, advanced neurologic manifestations at the primary stage, and unresectable tumors, and these factors are associated with poor treatment outcomes. Administration of bevacizumab (BV, Avastin(®)) promotes tumor regression and improves cerebral edema, and is expected to improve neurologic ...
openaire   +5 more sources

Relationship of Driver Oncogenes to Long-Term Pemetrexed Response in Non--Small-Cell Lung Cancer. [PDF]

, 2015
BackgroundPemetrexed is approved in the treatment of advanced stage nonsquamous non-small-cell lung cancer (NSCLC). The length of response is variable, and we thus sought to identify which clinicopathologic characteristics are associated with long-term ...
Liang, Ying, Neal, Joel W, Wakelee, Heather A   +2 more
core   +1 more source

Mammakarzinom: Bevacizumab nach Progression unter Bevacizumab? [PDF]

gynäkologie + geburtshilfe, 2017
Der Antikorper Bevacizumab hemmt mit dem VEGF („vascular endothelial growth factor“) ein Schlusselmolekul fur die Vaskularisierung von Tumorzellen. Profitieren Brustkrebspatientinnen mit einem Rezidiv nach der First-Line-Therapie mit Bevacizumab von dem VEGF-Antikorper in der Zweitlinie?
openaire   +3 more sources

Weekly versus three weeks chemotherapy for advanced ovarian cancer. A meta-analysis [PDF]

, 2016
Aim: Three weeks paclitaxel and carboplatin has been considered the standard of care for primary treatment of ovarian cancer (OC). Whether weekly therapy will further improve the clinical outcomes or not is still unclear.
De Felice, Francesca, Marchetti, Claudia, Monti, Marco, Musella, Angela, Musio, Daniela, Muzii, Ludovico, Palaia, Innocenza, Panici, Pierluigi Benedetti, Tombolini, Vincenzo   +8 more
core   +1 more source

Bevacizumab-Containing Chemoimmunotherapy for Recurrent Non-Small-Cell Lung Cancer after Chemoradiotherapy: Case Report

Medicina, 2021
Chemoimmunotherapy has become the standard of care as the first-line treatment of advanced or recurrent non-small-cell lung cancer (NSCLC). The bevacizumab-containing chemoimmunotherapy regimen is theoretically more effective than a non-bevacizumab ...
Nobutaka Kataoka, Yusuke Kunimatsu, Rei Tsutsumi, Nozomi Tani, Izumi Sato, Mai Tanimura, Takayuki Nakano, Keiko Tanimura, Daishiro Kato, Takayuki Takeda   +9 more
doaj   +1 more source

Anti epidermal growth factor receptor therapy in small bowel adenocarcinoma [PDF]

, 2018
Rationale:Small bowel adenocarcinoma (SBA) is an uncommon gastrointestinal cancer, thus limited data about treatment for advanced disease are available.
Anselmi, Elisabetta, Falcone, Rosa, Filetti, Marco, Marchetti, Paolo, Roberto, Michela   +4 more
core   +1 more source

Tumor clusters with divergent inflammation and human retroelement expression determine the clinical outcome of patients with serous ovarian cancer

Molecular Oncology, EarlyView.
Analysis of treatment‐naïve high‐grade serous ovarian carcinoma (HGSOC) and control tissues for ERVs, LINE‐1 (L1), inflammation, and immune checkpoints identified five clusters with diverse patient recurrence‐free survivals. An inflammation score was calculated and correlated with retroelement expression, where one novel cluster (Triple‐I) with high ...
Laura Glossner, Markus Eckstein, Christoph Mark, Matthias W. Beckmann, Arndt Hartmann, Pamela L. Strissel, Reiner Strick   +6 more
wiley   +1 more source

Efficacy and Safety of Bevacizumab Biosimilar (Encoda) Compared With Reference Bevacizumab (Avastin) in Patients With Metastatic Colorectal Cancer: A Multicenter, Real-World Study

Clinical Medicine Insights: Oncology
Background: The bevacizumab biosimilar (Encoda), which was approved by the National Medical Products Administration (NMPA) in China in 2019, is a biosimilar of bevacizumab.
Han Shan, Mengmeng Wang, Shuohan Huang, Hongyue Liu, Jiyong Liu, Qiong Du   +5 more
doaj   +1 more source

Reduced-Dose or Discontinuation of Bevacizumab Might Be Considered after Variceal Bleeding in Patients with Hepatocellular Carcinoma Receiving Atezolizumab/Bevacizumab: Case Reports

Medicina
Background and Objectives: Variceal bleeding (VB) is the most concerning condition that is difficult to treat after atezolizumab/bevacizumab in patients with advanced hepatocellular carcinoma (HCC).
Kyeong-Min Yeom, Young-Gi Song, Jeong-Ju Yoo, Sang Gyune Kim, Young Seok Kim   +4 more
doaj   +1 more source